PARABOLIC DRUGS (India) Financial Analysis

<div class='circular--portrait' style='background:#2A0CD0;color: white;font-size:4em;padding-top: 25px;;'>PA</div>
The current investor indifference towards the small price fluctuations of PARABOLIC DRUGS may encourage investors to take a closer look at the entity as it closed today at a share price of 0.0 on very low momentum in trading volume. The company management did not add any value to PARABOLIC DRUGS investors in January. However, most investors can still diversify their portfolios with PARABOLIC DRUGS to hedge your portfolio against high-volatility market scenarios. The stock standard deviation of daily returns for 30 days (very short) investing horizon is currently 0.0. The very small Stock volatility is a good signal to investors with longer term investment horizons. The PARABOLIC DRUGS financial analysis interface makes it easy to digest most current publicly released information about PARABOLIC DRUGS as well as get updates on important government artifacts including earning estimates, SEC corporate filings and announcements. This module also helps to analyze PARABOLIC DRUGS price relationship with some important fundamental indicators such as market cap and management efficiency. Check out Your Equity Center.


The company recorded loss per share of 17.46. PARABOLIC DRUGS had not issued any dividends in recent years. Parabolic Drugs Limited develops, manufactures, sells, and exports medicinal chemicals, botanical products, and active pharmaceutical ingredients and intermediates. To find out more about PARABDRUGS-EQ.NS contact the company at 91 17 2391 4638 or learn more at http://www.parabolicdrugs.com.


PARABOLIC DRUGS is not yet fully synchronised with the market data
PARABOLIC DRUGS has some characteristics of a very speculative penny stock
PARABOLIC DRUGS has high likelihood to experience some financial distress in the next 2 years
PARABOLIC DRUGS has high financial leverage indicating that it may have difficulties to generate enough cash to satisfy its financial obligations
The company has accumulated 4.21 B in total debt with debt to equity ratio (D/E) of 265.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. PARABOLIC DRUGS has Current Ratio of 0.26 indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due.
The entity reported revenue of 810.9 M. Net Loss for the year was (1.08 B) with loss before overhead, payroll, taxes, and interest of (119 M).

Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 473.41 M.


The company has Profit Margin (PM) of (133.3) % which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (116.2) % which suggests for every $100 dollars of sales it generated a net operating loss of -1.16.

Management Efficiency

PARABOLIC DRUGS has return on total asset (ROA) of (11.19) % which means that it has lost $11.19 on every $100 spent on asset. This is way below average.

PARABOLIC DRUGS Technical and Predictive Indicators

Did you try this?

Run Portfolio File Import Now


Portfolio File Import

Quickly import all of your third-party portfolios from your local drive in csv format
All  Next Launch Module
Check out Your Equity Center. Please also try Theme Ratings module to determine theme ratings based on digital equity recommendations. macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Company logos by clearbit